Ghent, NY, United States of America

Carl A Busacca


Average Co-Inventor Count = 2.0

ph-index = 1

Forward Citations = 3(Granted Patents)


Company Filing History:


Years Active: 1992

Loading Chart...
2 patents (USPTO):Explore Patents

Title: The Innovations of Carl A. Busacca

Introduction

Carl A. Busacca is a notable inventor based in Ghent, NY (US). He has made significant contributions to the field of pharmaceuticals, particularly in the development of novel compounds for treating cardiac arrhythmias. With a total of 2 patents to his name, his work continues to impact the medical community.

Latest Patents

Busacca's latest patents include the development of imidazo[2,2-b][3]benzazepine and pyrimido[2,1-b][3]benzazepine. These patents focus on novel imidazo[2,1-b][3]benzazepines and pyrimido[2,1-b][3]benzazepines of formula I, which are pharmaceutical compositions designed to treat cardiac arrhythmia in mammals. Additionally, he has worked on processes for synthesizing these compounds. Another significant patent involves imidazo[1,2-b][2]benzazepine and pyrimido[1,2-b][2]benzazepine, which also aims to provide methods for treating cardiac arrhythmias and includes processes for their synthesis.

Career Highlights

Carl A. Busacca has been associated with Sterling Drug Inc., where he has contributed to various innovative projects. His expertise in pharmaceutical chemistry has allowed him to develop compounds that address critical health issues.

Collaborations

Busacca has collaborated with Robert E. Johnson, enhancing the research and development efforts at Sterling Drug Inc. Their combined expertise has led to advancements in the pharmaceutical field.

Conclusion

Carl A. Busacca's contributions to pharmaceutical innovations demonstrate his commitment to improving healthcare through science. His patents reflect a dedication to developing effective treatments for cardiac arrhythmias, showcasing the importance of innovation in medicine.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…